Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532517 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device
A NA study, sponsored by Cerenovus, Part of DePuy Synthes Products.
- Terminated
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT02532517: Clinical Trial NA study, sponsored by Cerenovus, Part of DePuy Synthes Products.
NCT02532517 is a NA study that was terminated before completion, run by Cerenovus, Part of DePuy Synthes Products. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02532517, a NA study, was terminated before completion, sponsored by Cerenovus, Part of DePuy Synthes Products.
- TERMINATED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate effectiveness and safety of the CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System.
Primary Outcome
The Raymond-Roy Grading scale used for judging intracranial aneurysm (IA) endosaccular embolization success ranges from Grade I to III where, Grade I is completion occlusion with no flow of contrast seen in the aneurysm sac, Grade II is partial occlusion with some flow or eddy flow in the aneurysm sac and Grade III is residual aneurysm or Incomplete occlusion with apparent flow in the aneurysm sac. RCAO was assessed by the Independent Core Laboratory, complete aneurysm occlusion is defined as an
Interventions
- DEVICE CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2019-09-21 |
| Phase | NA |
Why NCT02532517 stopped before completion
NCT02532517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System is the first listed.
NCT02532517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02532517 about?
NCT02532517 is a clinical study titled "Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device". The purpose of this study is to demonstrate effectiveness and safety of the CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System.
What is the current status of trial NCT02532517?
This trial is currently terminated. It is a NA study. The enrollment target is 45 participants. The study started on 2015-09-01. Estimated completion is 2019-09-21.
What interventions are being tested in trial NCT02532517?
The interventions under investigation include: CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System (DEVICE).
Who is sponsoring clinical trial NCT02532517?
This trial is sponsored by Cerenovus, Part of DePuy Synthes Products, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02532517's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI